INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Nyxoah S.A. and its officers or directors [1] Group 1: Company Developments - On March 25, 2025, Nyxoah announced that the FDA issued an Approvable Letter for its Pre-Market Approval application for the Genio® system, indicating that the application substantially meets regulatory requirements [3] - The FDA's approval is contingent upon satisfactory completion of a review of manufacturing facilities, methods, and controls [3] - Following the announcement, analysts projected a delay in the commercial launch of the Genio system pending further FDA review [3] Group 2: Market Reaction - Nyxoah's stock price fell by $2.42 per share, or 21.36%, closing at $8.91 per share on March 26, 2025, in response to the news [4]